Business Context and Reporting Period
Tvardi Therapeutics, Inc. (TVRD) filed a Form 8-K on March 6, 2026, to announce the scheduling of its 2026 Annual Meeting of Stockholders. The meeting is set for June 9, 2026. The company is incorporated in Delaware and trades on The Nasdaq Stock Market LLC.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and meeting logistics rather than financial performance.
Material Changes
No material financial changes or operational updates were reported in this filing. The primary event is the establishment of the 2026 Annual Meeting date and the associated deadlines for stockholder proposals.
Guidance, Outlook, and Governance Deadlines
- Annual Meeting Date: June 9, 2026.
- Stockholder Proposals (Rule 14a-8): Proposals intended for inclusion in the proxy statement must be received by March 16, 2026.
- Director Nominations and Other Matters (Bylaws): Notices for director nominations or other business must be received by March 16, 2026.
- Universal Proxy Rule (Rule 14a-19): Stockholders intending to solicit proxies for director nominees other than the Company's nominees must provide notice by April 10, 2026.
Key Facts for Investor Verification
- Verify the exact date of the 2026 Annual Meeting (June 9, 2026) against the company's investor relations calendar.
- Confirm the March 16, 2026 deadline for submitting stockholder proposals and director nominations to ensure compliance with the company's Bylaws.
- Note the April 10, 2026 deadline for universal proxy solicitations under Rule 14a-19.
- Check subsequent filings for the official proxy statement to review specific agenda items and management proposals.